- Home
- COCP vs CYTH Comparison
COCP vs CYTH Comparison
Compare COCP & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- CYTH
- Stock Information
- Founded
- COCP N/A
- CYTH 1990
- Country
- COCP United States
- CYTH United States
- Employees
- COCP N/A
- CYTH N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- CYTH Health Care
- Exchange
- COCP Nasdaq
- CYTH Nasdaq
- Market Cap
- COCP 18.3M
- CYTH 20.4M
- IPO Year
- COCP N/A
- CYTH N/A
- Fundamental
- Price
- COCP $1.99
- CYTH $0.66
- Analyst Decision
- COCP Strong Buy
- CYTH Buy
- Analyst Count
- COCP 1
- CYTH 3
- Target Price
- COCP $7.00
- CYTH $0.95
- AVG Volume (30 Days)
- COCP 14.9K
- CYTH 41.7K
- Earning Date
- COCP 11-13-2024
- CYTH 11-14-2024
- Dividend Yield
- COCP N/A
- CYTH N/A
- EPS Growth
- COCP N/A
- CYTH N/A
- EPS
- COCP N/A
- CYTH N/A
- Revenue
- COCP N/A
- CYTH $870,725.00
- Revenue This Year
- COCP N/A
- CYTH N/A
- Revenue Next Year
- COCP N/A
- CYTH $24.49
- P/E Ratio
- COCP N/A
- CYTH N/A
- Revenue Growth
- COCP N/A
- CYTH N/A
- 52 Week Low
- COCP $1.33
- CYTH $0.57
- 52 Week High
- COCP $3.10
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- COCP 51.27
- CYTH 47.76
- Support Level
- COCP $1.83
- CYTH $0.60
- Resistance Level
- COCP $2.07
- CYTH $0.66
- Average True Range (ATR)
- COCP 0.11
- CYTH 0.05
- MACD
- COCP -0.01
- CYTH 0.00
- Stochastic Oscillator
- COCP 44.74
- CYTH 46.67
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.